Statements

September 2020

September 1, 2020 9/1/2020 Update on the U.S. Development Program for the Investigational Subcutaneous Formulation of ENTYVIO® (vedolizumab) as a Maintenance Therapy in Adults with Moderate to Severe Ulcerative Colitis

June 2020

June 22, 2020 6/22/2020 Update of the Financial Impact of the European Commission’s Decision to Release Takeda from Commitment to Divest Shire’s Pipeline Compound SHP647

June 17, 2020 6/17/2020 Regarding a Warning Letter from the U.S. Food and Drug Administration

June 2019

June 5, 2019 6/5/2019 Takeda Provides Update on TOURMALINE-AL1 Phase 3 Trial

January 2019

January 3, 2019 1/3/2019 Takeda Notes Court Sanction of the Scheme of Arrangement with respect to the Acquisition of Shire plc

October 2018

October 26, 2018 10/26/2018 Takeda comments on ongoing Phase 1 review by the European Commission of the proposed acquisition of Shire plc

May 2018

May 8, 2018 5/8/2018 Takeda Statement Regarding Press Reports

April 2018

April 24, 2018 4/24/2018 Takeda Statement Regarding Shire plc

April 20, 2018 4/20/2018 Takeda Statement Regarding Improved Proposal for Shire plc